Supplementary Table S1: Pharmacokinetics of the Components of DEC-C[a] (12)

Parameter	Decitabine	Cedazuridine
General Information		
Dose proportionality	20 mg to 40 mg with cedazuridine (100 mg)	40 to 100 mg with decitabine (20 mg)
With the recommended dosage of DEC-C for 5 consecutive days:		
5-day cumulative AUC, ng·hr/mL	851 (50%)	--
Day 1 AUC, ng·hr/mL	103 (55%)	2950 (49%)
Steady state AUC, ng·hr/mL	178 (53%)	3291 (45%)
Time to steady state, days	2	2
Accumulation ratio based on AUC	1.7 (42%)	1.1 (63%)
C_{max}, ng/mL	145 (55%)	371 (52%)
Absorption		
Bioavailability	Cedazuridine increases oral decitabine exposure	20% (23%)
Elimination		
Half-life at steady state,[b] hours	1.5 (27%)	6.7 (19%)
Metabolism		
Primary Pathways	Primarily by cytidine deaminase (CDA) and by physicochemical degradation	Conversion to epimer by physicochemical degradation
Excretion (healthy subjects)		
Total (% unchanged)	--	46% (21%) in urine and 51% (27%) in feces
Drug-Drug Interaction		
	Cedazuridine increases oral decitabine exposure	No effect of decitabine on cedazuridine
	• DEC-C may increase systemic exposure of drugs metabolized by CDA. • Proton pump inhibitors had no clinically meaningful effect on the exposures of DEC-C	

[a] Mean (% coefficient of variation)
[b] Mean (standard deviation)

Abbreviations: $AUC_{0\text{-}24h}$=area under the plasma concentration-time curve from time zero to 24 hours; C_{max}, maximum plasma concentration; T_{max}, time to maximum concentration; V/F, apparent volume of distribution; CL/F, apparent clearance.